Cancer, Depression, Anxiety, Survivorship
Conditions
Brief summary
The purpose of this research is to assess the feasibility of administering a telephone-based intervention to treat depression and anxiety in Hispanic cancer survivors.
Detailed description
Primary Objectives * To assess the feasibility (participation, accrual, retention, adherence) of administering the intervention in Hispanic cancer survivors. * To culturally adapt an existing behavioral intervention for cancer survivors based on stakeholder feedback. Exploratory Objectives * To summarize emotional distress (anxiety, depressive symptoms) and fear of recurrence in these post-treatment Hispanic cancer survivors. * To describe the therapy process in terms of satisfaction with treatment and the therapist-participant relationship.
Interventions
BEHAVIORALTelephone interview
Interested participants will complete a telephone interview to determine eligibility for the study. If found to be eligible for the study, participants will be registered and set up a time to speak with an assigned study coach.
BEHAVIORALCognitive Behavioral Therapy
Participants will speak with their assigned coach over the phone for 12 weeks to discuss the cognitive behavioral therapy (CBT) study workbook and provide feedback. CBT is a type of treatment that teaches people different ways to handle anxiety and/or depressive symptoms, such as by relaxing the body, changing thoughts, and solving problems. Participants will receive a workbook focused on teaching these strategies.
Sponsors
National Cancer Institute (NCI)
Wake Forest University Health Sciences
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Inclusion: age greater than or equal to 18 years; * Self-identify as Hispanic ethnicity * Score greater than or equal to 10 on the General Anxiety Disorder (GAD)-7 and/or greater than or equal to 8 on the Patient Health Questionnaire (PHQ)-9 * History of (1) treated (newly diagnosed or recurrent) solid tumor cancers (Stage I, II, or III); (2) any stage lymphoma (Hodgkin's or non-Hodgkin's); (3) acute leukemia in remission for more than a year; (4) chronic myelogenous leukemia with stable disease (chronic phase disease); or (5) chronic lymphocytic leukemia (CLL) not requiring treatment or a change in treatment for more than 6 months. * 6-60 months post-treatment (surgery, chemotherapy, and/or radiation therapy) for cancer (If only received active surveillance for prostate cancer or lymphoma with no other cancer treatment, participant is ineligible.) The timeframe applies to the most recent completion of treatment if a participant had a cancer recurrence. It is acceptable to be on hormonal/maintenance therapies. * Must be able to speak, read, and understand Spanish or English. * Resides in North Carolina.
Exclusion criteria
* Current psychotherapy \[regular appointment(s) with a mental health provider within the last 30 days\] * Self-reported active alcohol or substance abuse within the last 30 days * Past history of prostate cancer or non-Hodgkin's lymphoma with only active surveillance (i.e., no surgery, chemotherapy, or radiation therapy) * Progressive cancer * Global cognitive impairment based on self-reported diagnosis of dementia. * Self-reported psychotic symptoms in the last 30 days (Item in Screening Form: Have you seen things that aren't really there or have you heard voices when no one else was around within the last 30 days?) * Active suicidal ideation with plan and intent * Any change in psychotropic medications within the last 30 days * Hearing loss that would preclude participating in telephone sessions (determined by brief hearing assessment administered by research staff). Individuals who can compensate for hearing loss through the use of a hearing device or TDD phone, and through the use of such devices are able to communicate with the study therapist by telephone, will be included. If the therapist cannot communicate with the participant by telephone, the participant will be excluded. * Failure/inability/unwillingness to provide names and contact information for two family members or friends to serve as emergency contacts during the course of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Participation Rate - Percentage Who Agreed to Participate | 12 weeks after start of intervention | To determine participation rate, investigators will track the total number of individuals approached, the number of individuals who met all eligibility criteria and percent who agree to participate. |
| Accrual Rate | 12 weeks after start of intervention | Accrual rates will be calculated by calculating the mean number of participants recruited per month. |
| Retention Rate - Percentage of Completed Visits | 13 weeks after the start of intervention | Study retention will be estimated by the proportion of participants who complete the Week 13 visit. Drop-out is defined as 100% minus the dropout % |
| Adherence - Percentage of Completed Therapy Sessions | 12 weeks after start of intervention | Intervention adherence will be estimated as the mean percentage of therapy or check-in sessions each participant completes. Participants must complete at least 9 of the 12 sessions (75%) to be considered adherent. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Depressive Symptoms Questionnaire - Patient Health Questionnaire (PHQ)-9 | At baseline, 7 weeks and 13 weeks after start of intervention | The Patient Health Questionnaire (PHQ)-9 is a self-report measure of DSM-IV symptoms of Major Depressive Disorder. Participants rate how often they have experienced nine symptoms over the past 2 weeks on a scale of 0 (not at all); 1 (several days), 2 (more than half the days) and 3 (nearly every day). Responses are summed, with higher scores indicating greater depressive symptomatology. Scoring scale = 0-27 (scores 0 to less than or equal to 7 = no/mild depressive symptoms; scores greater than or equal to 8 to less than or equal to 14 = moderate depressive symptoms; scores greater than or equal to 15 to 27 = severe depressive symptoms) |
| Fear of Cancer Recurrence Inventory Questionnaire | At baseline and 13 weeks after start of intervention | The Fear of Cancer Recurrence Inventory (FCRI; severity subscale) will be used to measure self-reported fear of recurrence. This 9-item subscale measures the presence and severity of the intrusive thoughts or images associated with the fear of recurrence. Scoring scale ranges from 0 (not at all or never) to 4 (a great deal or all of the time). Score ranges from 0-36. The higher the score, the greater the participants' fear of recurrence. |
| Anxiety Questionnaire - General Anxiety Disorder (GAD)-7 | At baseline, 7 weeks and 13 weeks after start of intervention | The General Anxiety Disorder (GAD)-7 is a self-report measure of DSM-IV symptoms of general anxiety disorder. Participants rate 7 questions on a scale of 0 (not at all), 1 (several days), 2 (more than half the days) and 3 (nearly every day); one additional question assesses the interference of these symptoms with functioning. The first 7 questions are summed to create a total score. Scoring range is 0-21 with the higher score indicating a higher level of anxiety (scores 0 to less than or equal to 9 = no/mild anxiety; scores greater than or equal to 10 to less than or equal to 14 = moderate anxiety; scores greater than or equal to 15 to 21 = severe anxiety). |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Telephone-Based Cognitive Behavioral Therapy Participants with moderate or severe anxiety and/or depressive symptoms will participate in the telephone-based intervention that consists of the CBT workbook (15 minutes daily to complete exercises), plus psychotherapy delivered by telephone with a licensed bilingual mental health provider (45-50 minute sessions weekly).
Telephone interview: Interested participants will complete a telephone interview to determine eligibility for the study. If found to be eligible for the study, participants will be registered and set up a time to speak with an assigned study coach.
Cognitive Behavioral Therapy: Participants will speak with their assigned coach over the phone for 12 weeks to discuss the cognitive behavioral therapy (CBT) study workbook and provide feedback. CBT is a type of treatment that teaches people different ways to handle anxiety and/or depressive symptoms, such as by relaxing the body, changing thoughts, and solving problems. Participants will receive a workbook focused on teaching these strategies. | 8 |
| Total | 8 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Withdrawal by Subject | 1 |
Baseline characteristics
| Characteristic | Telephone-Based Cognitive Behavioral Therapy |
|---|---|
| Age, Continuous | 45.1 years STANDARD_DEVIATION 13.5 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 8 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race/Ethnicity, Customized Origin of Ethnicity - Honduras | 1 Participants |
| Race/Ethnicity, Customized Origin of Ethnicity - Mexico | 5 Participants |
| Race/Ethnicity, Customized Origin of Ethnicity - Nicaragua | 1 Participants |
| Race/Ethnicity, Customized Origin of Ethnicity - Spain | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 7 Participants |
| Race (NIH/OMB) White | 1 Participants |
| Region of Enrollment United States | 8 participants |
| Sex: Female, Male Female | 7 Participants |
| Sex: Female, Male Male | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 7 |
| other Total, other adverse events | 0 / 7 |
| serious Total, serious adverse events | 0 / 7 |
Outcome results
Primary
Accrual Rate
Accrual rates will be calculated by calculating the mean number of participants recruited per month.
Time frame: 12 weeks after start of intervention
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Telephone-Based Cognitive Behavioral Therapy | Accrual Rate | 1.1 participants accrued per month |
Primary
Adherence - Percentage of Completed Therapy Sessions
Intervention adherence will be estimated as the mean percentage of therapy or check-in sessions each participant completes. Participants must complete at least 9 of the 12 sessions (75%) to be considered adherent.
Time frame: 12 weeks after start of intervention
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Telephone-Based Cognitive Behavioral Therapy | Adherence - Percentage of Completed Therapy Sessions | 87.5 percentage to complete 9 or more session |
Primary
Participation Rate - Percentage Who Agreed to Participate
To determine participation rate, investigators will track the total number of individuals approached, the number of individuals who met all eligibility criteria and percent who agree to participate.
Time frame: 12 weeks after start of intervention
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Telephone-Based Cognitive Behavioral Therapy | Participation Rate - Percentage Who Agreed to Participate | 88.9 percentage of participants |
Primary
Retention Rate - Percentage of Completed Visits
Study retention will be estimated by the proportion of participants who complete the Week 13 visit. Drop-out is defined as 100% minus the dropout %
Time frame: 13 weeks after the start of intervention
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Telephone-Based Cognitive Behavioral Therapy | Retention Rate - Percentage of Completed Visits | 87.5 percentage of completion of Wk. 13 visit |
Secondary
Anxiety Questionnaire - General Anxiety Disorder (GAD)-7
The General Anxiety Disorder (GAD)-7 is a self-report measure of DSM-IV symptoms of general anxiety disorder. Participants rate 7 questions on a scale of 0 (not at all), 1 (several days), 2 (more than half the days) and 3 (nearly every day); one additional question assesses the interference of these symptoms with functioning. The first 7 questions are summed to create a total score. Scoring range is 0-21 with the higher score indicating a higher level of anxiety (scores 0 to less than or equal to 9 = no/mild anxiety; scores greater than or equal to 10 to less than or equal to 14 = moderate anxiety; scores greater than or equal to 15 to 21 = severe anxiety).
Time frame: At baseline, 7 weeks and 13 weeks after start of intervention
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Telephone-Based Cognitive Behavioral Therapy | Anxiety Questionnaire - General Anxiety Disorder (GAD)-7 | Baseline | 12.9 score on a scale | Standard Error 2 |
| Telephone-Based Cognitive Behavioral Therapy | Anxiety Questionnaire - General Anxiety Disorder (GAD)-7 | Week 7 | 4.3 score on a scale | Standard Error 2.3 |
| Telephone-Based Cognitive Behavioral Therapy | Anxiety Questionnaire - General Anxiety Disorder (GAD)-7 | Week 13 | 4.1 score on a scale | Standard Error 2.1 |
Secondary
Depressive Symptoms Questionnaire - Patient Health Questionnaire (PHQ)-9
The Patient Health Questionnaire (PHQ)-9 is a self-report measure of DSM-IV symptoms of Major Depressive Disorder. Participants rate how often they have experienced nine symptoms over the past 2 weeks on a scale of 0 (not at all); 1 (several days), 2 (more than half the days) and 3 (nearly every day). Responses are summed, with higher scores indicating greater depressive symptomatology. Scoring scale = 0-27 (scores 0 to less than or equal to 7 = no/mild depressive symptoms; scores greater than or equal to 8 to less than or equal to 14 = moderate depressive symptoms; scores greater than or equal to 15 to 27 = severe depressive symptoms)
Time frame: At baseline, 7 weeks and 13 weeks after start of intervention
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Telephone-Based Cognitive Behavioral Therapy | Depressive Symptoms Questionnaire - Patient Health Questionnaire (PHQ)-9 | Baseline | 11.9 score on a scale | Standard Error 2 |
| Telephone-Based Cognitive Behavioral Therapy | Depressive Symptoms Questionnaire - Patient Health Questionnaire (PHQ)-9 | Week 7 | 4.3 score on a scale | Standard Error 2.3 |
| Telephone-Based Cognitive Behavioral Therapy | Depressive Symptoms Questionnaire - Patient Health Questionnaire (PHQ)-9 | Week 13 | 4.1 score on a scale | Standard Error 2.1 |
Secondary
Fear of Cancer Recurrence Inventory Questionnaire
The Fear of Cancer Recurrence Inventory (FCRI; severity subscale) will be used to measure self-reported fear of recurrence. This 9-item subscale measures the presence and severity of the intrusive thoughts or images associated with the fear of recurrence. Scoring scale ranges from 0 (not at all or never) to 4 (a great deal or all of the time). Score ranges from 0-36. The higher the score, the greater the participants' fear of recurrence.
Time frame: At baseline and 13 weeks after start of intervention
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Telephone-Based Cognitive Behavioral Therapy | Fear of Cancer Recurrence Inventory Questionnaire | Baseline | 15.5 score on a scale | Standard Error 3.1 |
| Telephone-Based Cognitive Behavioral Therapy | Fear of Cancer Recurrence Inventory Questionnaire | Week 13 | 11.6 score on a scale | Standard Error 3.3 |